Los puntos clave no están disponibles para este artículo en este momento.
In this 52-week trial, adalimumab was more effective than placebo at inhibiting the progression of structural joint damage, reducing the signs and symptoms, and improving physical function in patients with active RA who had demonstrated an incomplete response to MTX.
Keystone et al. (Sat,) studied this question.